We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+2.58%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
-$12.9M
Cap. Flow
+$54.2M
Cap. Flow %
4.96%
Top 10 Hldgs %
67.6%
Holding
30
New
7
Increased
10
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$72M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$51.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$45M
4
PCRX icon
Pacira BioSciences
PCRX
+$36.8M
5
DVAX
Dynavax Technologies
DVAX
+$28.6M

Top Sells

Rank Stock Value
1
MDXG icon
MiMedx Group
MDXG
+$75.5M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$66.9M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$50.6M
4
ARGX icon
argenx
ARGX
+$49.5M
5
AMRN
Amarin Corp
AMRN
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 89.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
1
DELISTED
Radius Health, Inc.
RDUS
$104M 9.53%
2,900,893
+251,608
+9% +$9.09M
SPPI
2
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$99.8M 9.12%
6,203,356
-1,180,110
-16% -$23.4M
CORT icon
3
Corcept Therapeutics
CORT
$12.8B
$85.3M 7.8%
5,188,417
-591,089
-10% -$11M
TVTX icon
4
Travere Therapeutics
TVTX
$5.33B
$82.6M 7.55%
3,693,371
+48,933
+1% +$1.17M
PCRX icon
5
Pacira BioSciences
PCRX
$1.06B
$82.1M 7.5%
2,634,916
+1,032,582
+64% +$36.8M
UTHR icon
6
United Therapeutics
UTHR
$26.2B
$63.7M 5.82%
+566,926
New +$72M
NUVA
7
DELISTED
NuVasive, Inc.
NUVA
$57.4M 5.25%
1,099,523
+424,523
+63% +$21.5M
URGN icon
8
UroGen Pharma
URGN
$2B
$57M 5.2%
1,146,197
+229,747
+25% +$11.5M
IOVA icon
9
Iovance Biotherapeutics
IOVA
$2.09B
$54.2M 4.95%
3,206,073
+2,973,677
+1,280% +$45M
AMRN
10
Amarin Corp
AMRN
$298M
$53.4M 4.88%
886,497
-337,329
-28% -$25M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$312M
$51.8M 4.73%
+3,072,275
New +$51.4M
STML
12
DELISTED
Stemline Therapeutics, Inc.
STML
$39.9M 3.64%
2,606,598
+256,806
+11% +$4M
DVAX
13
DELISTED
Dynavax Technologies
DVAX
$32.9M 3.01%
+1,658,795
New +$28.6M
VCEL icon
14
Vericel Corp
VCEL
$2.43B
$30.9M 2.82%
3,104,592
-276,711
-8% -$2.29M
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$30.7M 2.81%
272,700
-402,792
-60% -$50.6M
OXFD
16
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$29.1M 2.66%
2,339,184
+1,219,297
+109% +$14.8M
PACB icon
17
Pacific Biosciences
PACB
$460M
$25.8M 2.36%
12,576,002
+5,510,082
+78% +$14.3M
SVRA icon
18
Savara
SVRA
$1.14B
$24.9M 2.28%
2,711,190
-44,822
-2% -$528K
QURE icon
19
uniQure
QURE
$2.93B
$24.6M 2.24%
+1,045,065
New +$22.8M
ADMA icon
20
ADMA Biologics
ADMA
$2.01B
$15.3M 1.4%
3,329,234
-38,401
-1% -$153K
CPRX
21
DELISTED
Catalyst Pharmaceutical
CPRX
$11.9M 1.09%
4,994,719
+521,112
+12% +$1.73M
CSII
22
DELISTED
Cardiovascular Systems, Inc.
CSII
$9.78M 0.89%
+446,100
New +$10.7M
ANIP icon
23
ANI Pharmaceuticals
ANIP
$1.83B
$8.32M 0.76%
142,943
-35
-0% -$2.22K
RARX
24
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.72M 0.71%
+1,454,761
New +$10.4M
CVRS
25
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$6.27M 0.57%
4,574,835
-1,411,170
-24% -$1.64M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Consonance Capital Management held 30 positions worth $1.09B, down 1.2% from $1.11B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Consonance Capital Management deployed $54.2M of net new capital in Q1 2018, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was United Therapeutics: 566,926 shares worth $63.7M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $50.6M trimmed.

  • Consonance Capital Management's largest Q1 2018 buy was United Therapeutics: 566,926 shares worth $63.7M.
  • Consonance Capital Management added most to Iovance Biotherapeutics in Q1 2018, an estimated $45M increase.
  • Consonance Capital Management's biggest Q1 2018 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $50.6M.
  • Consonance Capital Management fully exited MiMedx Group in Q1 2018, selling an estimated $75.5M.
  • Consonance Capital Management's ten largest holdings make up 68% of its $1.09B portfolio in Q1 2018.
  • Consonance Capital Management opened 7 new positions and closed 4 in Q1 2018.
  • Consonance Capital Management's portfolio value fell 1.2% quarter-over-quarter to $1.09B.

Based on Consonance Capital Management's 13F filing for Q1 2018, filed 15 May 2018.